Skip to main content
. 2007 Oct 25;117(11):3350–3358. doi: 10.1172/JCI32727

Figure 7. Efficacy of vvDD following delivery by different routes to tumor-bearing mouse models.

Figure 7

(A) Single i.v. injections of 1 × 109 PFU of viral strain vvDD or vaccinia Wyeth strain bearing a TK deletion were delivered to immunocompetent mice bearing subcutaneous TIB-75 tumors (50–100 mm3) (3 days after implantation; arrow). Tumor volume was measured by calipers (n = 8/group). *P = 0.04 for vvDD relative to Wyeth TK. (B) 1 × 109 PFU of vvDD was delivered intratumorally (i.t.) or i.p. to SCID mice bearing subcutaneous HT29 tumors or BALB/c mice bearing subcutaneous MC38 tumors. Kaplan-Meier survival curves were compared with those for the PBS-injected control group (n = 8/group). Mice were euthanized when tumors reached 1.4 cm3. P < 0.05 for all treatment groups relative to PBS.